189 related articles for article (PubMed ID: 16207346)
1. DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis.
van Riel PL; Fransen J
Arthritis Res Ther; 2005; 7(5):189-90. PubMed ID: 16207346
[TBL] [Abstract][Full Text] [Related]
2. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.
Vander Cruyssen B; Van Looy S; Wyns B; Westhovens R; Durez P; Van den Bosch F; Veys EM; Mielants H; De Clerck L; Peretz A; Malaise M; Verbruggen L; Vastesaeger N; Geldhof A; Boullart L; De Keyser F
Arthritis Res Ther; 2005; 7(5):R1063-71. PubMed ID: 16207323
[TBL] [Abstract][Full Text] [Related]
3. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
4. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
Flendrie M; Creemers MC; van Riel PL
Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
[TBL] [Abstract][Full Text] [Related]
5. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
Durez P; Van den Bosch F; Corluy L; Veys EM; De Clerck L; Peretz A; Malaise M; Devogelaer JP; Vastesaeger N; Geldhof A; Westhovens R
Rheumatology (Oxford); 2005 Apr; 44(4):465-8. PubMed ID: 15695306
[TBL] [Abstract][Full Text] [Related]
6. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
Pavelka K; Jarosová K; Suchý D; Senolt L; Chroust K; Dusek L; Vencovský J
Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
[TBL] [Abstract][Full Text] [Related]
8. Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.
Kuuliala A; Nissinen R; Kautiainen H; Repo H; Leirisalo-Repo M
Ann Rheum Dis; 2006 Jan; 65(1):26-9. PubMed ID: 15941839
[TBL] [Abstract][Full Text] [Related]
9. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
10. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis.
Gardiner PV; Bell AL; Taggart AJ; Wright G; Kee F; Smyth A; McKane R; Lee J; Rooney ME; Whitehead E
Ann Rheum Dis; 2005 Mar; 64(3):506-7. PubMed ID: 15708909
[No Abstract] [Full Text] [Related]
11. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.
Fransen J; Moens HB; Speyer I; van Riel PL
Ann Rheum Dis; 2005 Sep; 64(9):1294-8. PubMed ID: 15829574
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
[TBL] [Abstract][Full Text] [Related]
14. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care.
Pincus T; Yazici Y; Bergman MJ
Rheum Dis Clin North Am; 2009 Nov; 35(4):773-8, viii. PubMed ID: 19962621
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?
Yazici Y; Abramson SB
Bull NYU Hosp Jt Dis; 2007; 65(4):300-5. PubMed ID: 18081549
[TBL] [Abstract][Full Text] [Related]
16. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
Haraoui B; Cameron L; Ouellet M; White B
J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab.
Sakai Y; Sakai S; Otsuka T; Ohno D; Murasawa T; Munakata K; Mizuno K
Ther Apher Dial; 2009 Jun; 13(3):179-85. PubMed ID: 19527463
[TBL] [Abstract][Full Text] [Related]
18. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
Odai T; Matsunawa M; Takahashi R; Wakabayashi K; Isozaki T; Yajima N; Miwa Y; Kasama T
J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
[TBL] [Abstract][Full Text] [Related]
19. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
20. Assessing remission in clinical practice.
Mierau M; Schoels M; Gonda G; Fuchs J; Aletaha D; Smolen JS
Rheumatology (Oxford); 2007 Jun; 46(6):975-9. PubMed ID: 17341506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
